Desert hedgehog signaling molecule (DHH)

Desert hedgehog signaling molecule (DHH) is a secreted signaling protein and morphogen belonging to the Hedgehog family, encoded by the DHH gene located on chromosome 12q13.1. DHH is produced as a precursor that undergoes autoproteolytic cleavage, yielding a signaling-active N-terminal product that is lipid-modified, restricting it to cell membranes and mediating juxtacrine signaling. The protein is primarily expressed in gonadal Sertoli cells and Schwann cells, where it plays a critical role in male gonadal differentiation, testicular development, peripheral nerve sheath formation, and the maintenance of the perineurium. Loss-of-function mutations in DHH cause sex development disorders (such as 46,XY gonadal dysgenesis and Swyer syndrome) and neurological conditions (like minifascicular polyneuropathy). While DHH is involved in the canonical hedgehog signaling pathway—through binding to PTCH1 and PTCH2 receptors, relieving their inhibition on the Smoothened (SMO) receptor, and activating downstream GLI transcription factors—it is not a major drug target itself, as most pharmacologic agents focus on downstream signaling components, particularly Smoothened[1][3][5][7][8].

Other names

Desert hedgehogDesert hedgehog proteinDHH-NDesert hedgehog protein N-productHHG-3MGC35145GDMNGDXYMSRXY7Desert hedgehog homolog

Not directly targeted clinically; Hedgehog pathway antagonists (e.g., Smoothened inhibitors) generally inhibit pathway activation downstream of hedgehog ligands (such as DHH, SHH, IHH)